Free tool
FAERS Monitor: Claritin
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021952 or its brand name (Claritin, Loratadine). Reports on generic versions are filed under their own applications.
Reports
103,057
Serious
49,212
48% of reports
Hospitalization
22,956
Death reported
4,538
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective11,854
- fatigue6,591
- nausea5,790
- headache5,304
- dyspnoea4,791
- diarrhoea4,780
- off label use4,567
- dizziness4,289
- pain4,055
- rash3,368
- pruritus3,350
- cough3,083
- vomiting2,949
- arthralgia2,893
- somnolence2,821
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 965 |
| 2005 | 1,071 |
| 2006 | 1,067 |
| 2007 | 939 |
| 2008 | 1,073 |
| 2009 | 1,316 |
| 2010 | 1,637 |
| 2011 | 2,020 |
| 2012 | 3,015 |
| 2013 | 3,959 |
| 2014 | 4,683 |
| 2015 | 7,017 |
| 2016 | 8,555 |
| 2017 | 8,774 |
| 2018 | 7,746 |
| 2019 | 7,819 |
| 2020 | 7,024 |
| 2021 | 6,285 |
| 2022 | 6,083 |
| 2023 | 5,477 |
| 2024 | 5,990 |
| 2025 | 5,930 |
| 2026 | 4,611 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,951,102 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| somnolenceSignal | 2,821 | 2.9 | 2.8 | 3,459 |
| coughSignal | 3,083 | 2.3 | 2.2 | 2,163 |
| drug ineffective | 11,854 | 1.8 | 1.8 | 4,834 |
| pruritus | 3,350 | 1.8 | 1.7 | 1,169 |
| dizziness | 4,289 | 1.8 | 1.7 | 1,433 |
| fatigue | 6,591 | 1.7 | 1.7 | 2,108 |
| dyspnoea | 4,791 | 1.7 | 1.7 | 1,514 |
| headache | 5,304 | 1.7 | 1.7 | 1,679 |
| rash | 3,368 | 1.6 | 1.5 | 729 |
| diarrhoea | 4,780 | 1.5 | 1.5 | 857 |
| nausea | 5,790 | 1.5 | 1.5 | 984 |
| arthralgia | 2,893 | 1.4 | 1.4 | 368 |
| pain | 4,055 | 1.3 | 1.3 | 375 |
| vomiting | 2,949 | 1.3 | 1.2 | 185 |
| off label use | 4,567 | 1.1 | 1.0 | 19 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.